Vertex Pharmaceuticals | VRTX - Debt



Vertex Pharmaceuticals reported $1.53B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
Arrowhead Research USD 388.24M 21.18M Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Insmed USD 564.1M 567.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Merck USD 34.84B 2.27B Mar/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Sanofi 22.28B 1.24B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025